The FDA said that "serious data gaps" have hindered its ability to craft regulation, including a lack of information on ...
Agency is seeking comment from consumers on products.
Argenx SE (NASDAQ:ARGX) released topline data on Monday from the pivotal Phase 3 ADAPT SERON study of Vyvgart (IV: efgartigimod alfa-fcab). Part A of the trial randomized participants (1:1) to receive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback